Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 5/20 | 0.41 |
| ▸ | BMP1 | P13497 | 1/20 | 0.39 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.39 |
| ▸ | TASP1 | Q9H6P5 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2197432 | 0.96 | BMP1 (0.42) | BACE1BMP1ENPEPTASP1 | |
| SCHEMBL2182740 | 0.87 | BACE1 (0.45) | BACE1BMP1PTPN1 | |
| SCHEMBL11347512 | 0.85 | ENPEP (0.43) | ENPEP | |
| SCHEMBL2193153 | 0.84 | ENPEP (0.40) | BMP1ENPEPTASP1 | |
| SCHEMBL30730497 | 0.81 | NOD1 (0.41) | BACE1ENPEP | |
| SCHEMBL2196455 | 0.81 | ENPEP (0.42) | BMP1ENPEP | |
| SCHEMBL30432849 | 0.79 | BACE1 (0.50) | BACE1ENPEPTASP1PTPN1 | |
| SCHEMBL2194678 | 0.79 | BMP1 (0.44) | BACE1BMP1 | |
| SCHEMBL30563231 | 0.79 | TASP1 (0.43) | BACE1ENPEPTASP1 | |
| SCHEMBL29778366 | 0.78 | MME (0.43) | BACE1ENPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190070251-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS | 2019-03-07 | — | — | US | disclosed |
| US-9682153-B2 | Polymer conjugates of therapeutic peptides | NEKTAR THERAPEUTICS (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS | 2016-01-28 | — | — | US | disclosed |
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | BACE1 2543/4885BMP1 3740/4885ENPEP 19/4885 |
| US-20190070251-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | BACE1 2543/4885BMP1 3740/4885ENPEP 19/4885 |
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | DNPEP, VIP, PTMS | BACE1 1932/4885BMP1 1697/4885ENPEP 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.